Table 5.
Sensitivity Analyses by Omitting 1 RCT Each Time
| The Omitted RCT | RR (95% CI), P S, I2, P H | ||
|---|---|---|---|
| Stroke | CHD | CVD | |
| Albert, 200810 | 0.89 (0.82–0.95), P S=0.001, I2=29, P H=0.12 | 1.04 (0.99–1.10), P S=0.14, I2=0, P H=0.68 | 0.96 (0.92–0.99), P S=0.02, I2=23, P H=0.17 |
| Armitage, 201011 | 0.87 (0.81–0.94), P S<0.001, I2=27, P H=0.13 | 1.03 (0.96–1.10), P S=0.43, I2=0, P H=0.68 | 0.92 (0.88–0.99), P S=0.001, I2=0, P H=0.56 |
| Baker, 200239 | — | 1.03 (0.98–1.09), P S=0.20, I2=0, P H=0.83 | — |
| Bonaa, 200631 | 0.89 (0.83–0.96), P S=0.002, I2=34, P H=0.07 | 1.03 (0.98–1.09), P S=0.22, I2=0, P H=0.68 | 0.95 (0.91–0.99), P S=0.009, I2=15, P H=0.26 |
| Bostom, 201112 | 0.89 (0.83–0.96), P S=0.001, I2=32, P H=0.09 | 1.04 (0.98–1.09), P S=0.18, I2=0, P H=0.67 | 0.95 (0.92–0.99), P S=0.02, I2=22, P H=0.17 |
| Cole, 200746 | 0.89 (0.83–0.96), P S=0.001, I2=31, P H=0.10 | 1.04 (0.99–1.09), P S=0.18, I2=0, P H=0.68 | — |
| Ebbing, 200813 | 0.90 (0.84–0.96), P S=0.002, I2=34, P H=0.08 | 1.03 (0.98–1.09), P S=0.21, I2=0, P H=0.72 | 0.95 (0.92–0.99), P S=0.02, I2=21, P H=0.19 |
| Galan, 201014 | 0.90 (0.84–0.97), P S=0.003, I2=27, P H=0.13 | 1.04 (0.99–1.09), P S=0.14, I2=0, P H=0.69 | 0.96 (0.92–0.99), P S=0.03, I2=23, P H=0.17 |
| Heinz, 201050 | 0.90 (0.84–0.96), P S=0.002, I2=34, P H=0.08 | 1.04 (0.99–1.09), P S=0.16, I2=0, P H=0.67 | 0.96 (0.92–1.00), P S=0.03, I2=18, P H=0.23 |
| Hodis, 200948 | — | — | 0.96 (0.92–0.99), P S=0.02, I2=23, P H=0.17 |
| House, 201051 | 0.89 (0.83–0.96), P S=0.001, I2=25, P H=0.16 | 1.04 (0.99–1.09), P S=0.17, I2=0, P H=0.74 | — |
| Huo, 201526 | 0.92 (0.85–0.995), P S=0.04, I2=26, P H=0.14 | 1.04 (0.99–1.09), P S=0.16, I2=0, P H=0.67 | 0.97 (0.93–1.01), P S=0.12, I2=0, P H=0.48 |
| Imasa, 200949 | — | 1.04 (0.99–1.09), P S=0.17, I2=0, P H=0.69 | — |
| Jamison, 200716 | 0.90 (0.83–0.96), P S=0.002, I2=34, P H=0.07 | 1.05 (0.99–1.10), P S=0.09, I2=0, P H=0.80 | 0.96 (0.92–1.00), P S=0.04, I2=19, P H=0.21 |
| Lamas, 201324 | 0.90 (0.84–0.96), P S=0.002, I2=31, P H=0.10 | 1.04 (0.99–1.09), P S=0.14, I2=0, P H=0.68 | 0.96 (0.92–1.00), P S=0.03, I2=19, P H=0.21 |
| Lange, 200441 | — | 1.03 (0.98–1.08), P S=0.25, I2=0, P H=0.86 | — |
| Liem, 200442 | — | 1.04 (0.99–1.09), P S=0.15, I2=0, P H=0.68 | 0.96 (0.92–0.99), P S=0.02, I2=23, P H=0.17 |
| Liem, 200532, 33 | 0.90 (0.84–0.96), P S=0.002, I2=33, P H=0.08 | 1.04 (0.99–1.09), P S=0.17, I2=0, P H=0.69 | 0.96 (0.92–1.00), P S=0.03, I2=22, P H=0.18 |
| Lonn, 200617 | 0.91 (0.85–0.98), P S=0.008, I2=29, P H=0.12 | 1.05 (0.99–1.10), P S=0.11, I2=0, P H=0.70 | 0.96 (0.92–1.00), P S=0.03, I2=23, P H=0.17 |
| Mark, 199638 | 0.90 (0.84–0.97), P S=0.003, I2=30, P H=0.11 | — | — |
| Potena, 200847 | — | — | 0.96 (0.92–0.99), P S=0.02, I2=18, P H=0.23 |
| Righetti, 200340 | — | — | 0.96 (0.92–0.99), P S=0.02, I2=20, P H=0.20 |
| Righetti, 200644 | 0.90 (0.84–0.96), P S=0.002, I2=32, P H=0.09 | 1.04 (0.99–1.09), P S=0.14, I2=0, P H=0.71 | 0.96 (0.92–1.00), P S=0.03, I2=18, P H=0.23 |
| Schnyder, 200218 | — | 1.04 (0.99–1.09), P S=0.13, I2=0, P H=0.78 | — |
| Sharma, 201325 | — | 1.04 (0.99–1.09), P S=0.15, I2=0, P H=0.67 | — |
| Toole, 200419 | 0.88 (0.82–0.95), P S=0.001, I2=29, P H=0.12 | 1.04 (0.99–1.10), P S=0.12, I2=0, P H=0.70 | 0.95 (0.92–0.99), P S=0.02, I2=23, P H=0.17 |
| Vianna, 200730 | — | — | 0.96 (0.92–0.99), P S=0.02, I2=22, P H=0.18 |
| VITATOPS, 201037 | 0.89 (0.82–0.96), P S=0.003, I2=34, P H=0.08 | 1.04 (0.99–1.09), P S=0.16, I2=0, P H=0.67 | 0.96 (0.92–1.01), P S=0.09, I2=20, P H=0.21 |
| Wrone, 200443 | 0.89 (0.83–0.96), P S=0.001, I2=33, P H=0.08 | 1.04 (0.99–1.09), P S=0.17, I2=0, P H=0.70 | 0.95 (0.92–0.99), P S=0.02, I2=19, P H=0.21 |
| Zoungas, 200645 | 0.90 (0.84–0.96), P S=0.003, I2=27, P H=0.14 | 1.04 (0.99–1.09), P S=0.17, I2=0, P H=0.69 | 0.96 (0.92–0.99), P S=0.02, I2=22, P H=0.17 |
CHD indicates coronary heart disease; CVD, cardiovascular disease; P H, P value for heterogeneity; P S, P value for significance; RCT, randomized controlled trial; RR, relative risk.